Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...
(“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the ...
An open-label phase 1/2 study of DCC-3009 monotherapy in patients with advanced gastrointestinal stromal tumor. PYNNACLE Phase 1/2 basket study (NCT04585750). · Prior standard therapy or ineligible ...
Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatap ...
Anti-tumor effects of molecular glue BC. (a) Representative images of tumors in different treatment groups after 28 days. (b) Quantifications of anti-tumor activity of compound BC in the xenograft. (c ...
Morning Overview on MSN
How gene mutations disrupt cell growth and trigger cancer?
Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...
The results of research headed by a team in the lab of Michael Sigal, MD, at the Max Delbrück Center and Charité—Universitätsmedizin Berlin, have shed new light on the role of the p53 tumor suppressor ...
Figure 2: Schematic depicting hypothesized cooperation between HPV and COVID in suppressing p53 and contributing to cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results